One-third of all #stroke survivors, approximately 250,000 new people each year in the USA, suffer from #aphasia. Aphasia is an impairment in the ability to understand or use language. A research article suggests that cerebellar #tDCS as a possible treatment for aphasia.
Being a #non-invasive technology, wouldn't it be nice if tDCS becomes a standard procedure for patients with aphasia?
Lone Star NeuroMODULATION
LSN is targeting unmet clinical needs by creating disruptive device platforms that offer promising solutions for lowering costs, realizing higher returns and effectively addressing more therapeutic indications if adopted for medical applications.